Internal Medicine, Pulmonary Disease · Miami, FL
NPI
1376541961
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3181 SW 22 Street, 2nd Floor
Miami, FL, 33145
Phone (305) 567-1999
Groups this clinician bills Medicare through
Medicare paid, 2024
$138K
2,336 services
Medicare patients, 2024
425
Average age 75
Drug cost, 2024
$11.3M
85,664 prescriptions
Company payments, 2025
$818
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jorge Sanchez-Masiques was code 99214 (office e&m - established), 695 times for 348 patients. In total Jorge Sanchez-Masiques billed 2,336 services in 19 codes, and Medicare paid $138K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-06-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 695 | 348 | $108.83 | $76K |
| 94664 E&M - Miscellaneous | Office | 420 | 272 | $16.17 | $6,791 |
| 71046 X-ray - Chest | Office | 287 | 243 | $28.26 | $8,110 |
| 94060 Pulmonary Function Testing | Office | 188 | 186 | $33.39 | $6,277 |
| 94727 Pulmonary Function Testing | Office | 184 | 182 | $39.02 | $7,180 |
| 94729 Pulmonary Function Testing | Office | 183 | 181 | $49.11 | $8,987 |
| 99204 Office E&M - New | Office | 124 | 124 | $139.02 | $17K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 110 | 76 | $0.76 | $83.3 |
| 99406 Behavioral Health Services | Office | 44 | 35 | $16.78 | $738 |
| 94618 Pulmonary Function Testing | Office | 37 | 36 | $29.09 | $1,076 |
| G0296 Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 29 | 26 | $31.10 | $902 |
| 70220 Standard X-ray | Office | 14 | 14 | $33.45 | $468 |
By year: 2022 $137K for 2,149 services; 2023 $129K for 1,979 services; 2024 $138K for 2,336 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jorge Sanchez-Masiques prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 17,876 prescriptions and refills. In total Jorge Sanchez-Masiques wrote 85,664 Medicare prescriptions that cost $11.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 17,876 | 19,978 | 3,454 | $451K |
| Fluticasone Propionate Generic | 13,971 | 19,682 | 3,088 | $144K |
| Montelukast Sodium Generic | 8,736 | 14,116 | 1,917 | $37K |
| Ipratropium Bromide Generic | 7,588 | 14,332 | 2,040 | $235K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 4,171 | 4,675 | 786 | $360K |
| Azelastine Hcl Generic | 3,899 | 5,541 | 837 | $84K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 3,564 | 3,717 | 683 | $2.4M |
| Symbicort Budesonide/Formoterol Fumarate | 2,730 | 3,107 | 670 | $644K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 2,187 | 2,364 | 510 | $151K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 2,181 | 2,459 | 506 | $352K |
| Ventolin Hfa Albuterol Sulfate | 1,935 | 2,022 | 542 | $105K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 1,712 | 1,779 | 382 | $1.1M |
| Spiriva Respimat Tiotropium Bromide | 1,668 | 1,716 | 326 | $874K |
| Breyna Budesonide/Formoterol Fumarate | 1,533 | 1,874 | 389 | $208K |
| Spiriva Handihaler Tiotropium Bromide | 1,302 | 1,358 | 229 | $676K |
Brand drugs: - claims; generic drugs: 51,045 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jorge Sanchez-Masiques $818 ($818 in general payments such as food, travel and fees) from 5 companies. The largest payer was GlaxoSmithKline, LLC. with $232.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.